PMID- 34232825
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20220426
IS  - 1532-4192 (Electronic)
IS  - 0735-7907 (Linking)
VI  - 39
IP  - 9
DP  - 2021 Oct
TI  - Perineural Invasion as a Prognostic Factor in Laryngeal Squamous Cell Cancer: A 
      Matched-Pair Survival Analysis.
PG  - 734-740
LID - 10.1080/07357907.2021.1947311 [doi]
AB  - BACKGROUND: The purpose of this study was to compare survival outcomes in 
      patients with perineural invasion (PNI)-positive laryngeal squamous cell 
      carcinoma (LSCC) and patients with PNI-negative LSCC. METHODS: A total of 1,272 
      patients with LSCC, diagnosed between 2008 and 2017, were included in this study. 
      LSCC Patients with and without PNI were matched based on possible confounding 
      factors. Survival analysis was performed using Kaplan-Meier estimates and the Cox 
      proportional hazards model. RESULTS: Of the 1,272 LSCC patients, 118 (9.28%) were 
      positive for PNI. Compared to PNI-negative patients, PNI-positive LSCC patients 
      had significantly worse overall survival (OS) (p = 0.017), disease-specific 
      survival (DSS) (p = 0.034) and recurrence-free survival (RFS) (p = 0.002). After 
      pair matching, cohorts consisted of 118 patients in the PNI-positive group and 
      118 in the PNI-negative group. Significantly increased risk of OS (HR, 2.17; 95% 
      confidence interval [CI], 1.29-3.61, p = 0.003), DSS (HR, 2.07; 95% CI, 
      1.32-3.24, p = 0.004) and RFS (HR, 2.65; 95% CI, 1.59-4.40, p < 0.001) was 
      observed after adjustment for prognostic variables. CONCLUSIONS: Patients with 
      PNI-positive LSCC have significantly worse survival outcomes compared to patients 
      with PNI-negative LSCC.
FAU - Zhu, Xiaoli
AU  - Zhu X
AD  - Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College 
      Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 
      Beijing, China.
FAU - Duan, Fei
AU  - Duan F
AD  - Department of Otolaryngology-Head and Neck Surgery, Jiujiang NO. 1 People's 
      Hospital, Jiangxi, China.
FAU - Zhu, Yingying
AU  - Zhu Y
AD  - Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College 
      Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 
      Beijing, China.
FAU - Shi, Xiaohua
AU  - Shi X
AD  - Department of Pathology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Sun, Shuai
AU  - Sun S
AD  - Department of Radiation Oncology, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Cheng, Yuejuan
AU  - Cheng Y
AD  - Department of Medical Oncology, Peking Union Medical College Hospital, Peking 
      Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Chen, Xingming
AU  - Chen X
AUID- ORCID: 0000-0002-9930-2185
AD  - Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College 
      Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, 
      Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210901
PL  - England
TA  - Cancer Invest
JT  - Cancer investigation
JID - 8307154
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*pathology/surgery
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Outcome Assessment, Health Care/*methods/statistics & numerical data
MH  - Peripheral Nerves/*pathology
MH  - Prognosis
MH  - Proportional Hazards Models
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - matched-pair analysis
OT  - perineural invasion
OT  - survival analysis
EDAT- 2021/07/08 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/07/07 17:16
PHST- 2021/07/08 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2021/07/07 17:16 [entrez]
AID - 10.1080/07357907.2021.1947311 [doi]
PST - ppublish
SO  - Cancer Invest. 2021 Oct;39(9):734-740. doi: 10.1080/07357907.2021.1947311. Epub 
      2021 Sep 1.